NCT07410806
HEALEY ALS Platform Trial - Regimen I NUZ-001
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentMerit E. Cudkowicz, MDInvestigator-initiated
~240 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:NUZ-001Matching placebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Disease Progression
Measured over Baseline to 36 Weeks
Conditions
Where it's being run
1 sites across 1 statesMassachusetts1
Study leadership
- Merit Cudkowicz, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Disease ProgressionBaseline to 36 Weeks
Change in disease severity over time as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score and survival. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.